Investigating a new pathway for repairing myelin in Multiple Sclerosis
GLT-1/EAAT2 signaling as a novel player in myelin repair
This study is looking at how a certain process in the brain might help repair the protective covering around nerves in people with Multiple Sclerosis, with the hope of finding new treatments that could improve their quality of life and slow down the disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10989063 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific signaling pathway involving glutamate may contribute to the repair of myelin in the central nervous system, particularly in patients with Multiple Sclerosis (MS). The study aims to identify new therapeutic targets that could promote myelin regeneration, which is crucial for restoring function and reducing disability in MS patients. By exploring the mechanisms behind myelin repair, the research seeks to develop innovative treatments that go beyond current therapies, which primarily address inflammation. Patients may benefit from potential new therapies that could enhance their quality of life and slow disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Multiple Sclerosis, particularly those experiencing progressive symptoms.
Not a fit: Patients with other neurological conditions unrelated to myelin damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that promote myelin repair, potentially improving outcomes for patients with Multiple Sclerosis.
How similar studies have performed: While the approach of targeting myelin repair is still emerging, there is growing evidence from other studies suggesting that promoting myelin regeneration could significantly impact MS treatment.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Fuss, Babette — Virginia Commonwealth University
- Study coordinator: Fuss, Babette
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.